| Literature DB >> 32825160 |
Weidong Qiang1, Tingting Gao1, Xinxin Lan1, Jinnan Guo1, Muhammad Noman1, Yaying Li1, Yongxin Guo1, Jie Kong1, Haiyan Li1, Linna Du1, Jing Yang1.
Abstract
We set out to assess the NIH/3T3 cell proliferation activity of Arabidopsis oil body-expressed recombinant oleosin-hEGF-hEGF protein. Normally, human epidermal growth factor (hEGF) is purified through complex process, however, oleosin fusion technology provides an inexpensive and scalable platform for its purification. Under a phaseolin promoter, we concatenated oleosin gene to double hEGF (hEGF-hEGF) with plant-preferred codons in the expression vectors and the construct was transformed into Arabidopsis thaliana (Arabidopsis). The transgenic Arabidopsis was validated by RT-PCR and the content of recombinant protein oleosin-hEGF-hEGF was quantified by western blot. Subsequently, the proliferation assay and transdermal absorption were determined by MTT method and immunohistochemical staining, respectively. First, the expression level of hEGF was recorded to be 14.83-ng/μL oil body and due to smaller size transgenic oil bodies expressing the recombinant oleosin-hEGF-hEGF, they were more skin permeable than those of control. Second, via the staining intensity of transgenic oil bodies was greater than EGF at all time points via immunohistochemical staining in transdermal absorption process. Lastly, activity assays of oil bodies expressed oleosin-hEGF-hEGF indicated that they stimulated the NIH/3T3 cell proliferation activity. Our results revealed oil-body-expressed oleosin-hEGF-hEGF was potential new material having implications in the field of medicine.Entities:
Keywords: epidermal growth factor; oil body; proliferation activity; transdermal absorption
Mesh:
Substances:
Year: 2020 PMID: 32825160 PMCID: PMC7564230 DOI: 10.3390/genes11090959
Source DB: PubMed Journal: Genes (Basel) ISSN: 2073-4425 Impact factor: 4.096
Figure 1Construction and detection of pOTB–hEGF–hEGF. (A) Schematic diagram of T-DNA region from pOTB–hEGF–hEGF; (B) PCR detection of recombinant plasmid; (C) T3 transgenic Arabidopsis seeds were determined by RT–PCR; (M) DNA2000 marker; 1—negative control (wild type); 2–7—T3 transgenic seeds; 8—negative control (water); 9—positive control (pOTB–hEGF–hEGF plasmid).
Figure 2Protein expression from T3 transgenic Arabidopsis. (A) western blot; (B) grayscale values and (C) the standard curve of the grayscale values from various concentrations of hEGF standard protein; (D) SDS-PAGE of the oil body; (E) western blot of fusion protein and (F) quantitation of fusion protein from T3 Arabidopsis seeds. M—protein marker; 1–6—oil body in T3 Arabidopsis; WT—oil bodies from WT Arabidopsis.
Figure 3Measurement and observation of size and microstructure from transgenic oil body and normal oil body. (A) Particle size; (B) microstructure observation; (a) dyed normal oil bodies via Nile red; (b) dyed transgenic oil bodies via Nile red. The images were shown at 40 × 10 magnification (scale bars = 10 µm). ** p < 0.01 vs. normal group.
Figure 4Analysis of hEGF protein and oleosin–hEGF–hEGF activation stability. (A) SDS-PAGE analysis of hEGF standard protein digested with protease at different times; (B) SDS-PAGE analysis of oleosin–hEGF–hEGF digested with protease at different times; (M) protein marker, 1–7—hydrolyzed protein of 0, 10, 15, 30, 45, 60, 90 min.
Figure 5Ability of transgenic oil bodies bound hEGF to infiltrate into skin. The immunohistochemistry analysis of drug absorption at different times is shown. hEGF protein is the positive group and saline is the negative control group. Images shown at 40 × 10 magnification (scale bars = 50 µm).
Figure 6Analysis of activation of p-EGFR. Activation of p-EGFR after (A) oleosin–hEGF–hEGF; (B) hEGF standard protein; (C) normal saline and (D) WT oil body treatments 1–3.
Figure 7Dose–response curves for proliferation activity. Increase of NIH/3T3 fibroblast cells were expressed as the percentage increases in absorbance (570/630 nm).